No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
300142 Walvax Biotechnology
- 12.19
- +0.30+2.52%
Market Closed Feb 14 15:00 CST
19.50BMarket Cap158.31P/E (TTM)
12.28High11.85Low353.59KlotVolume11.88Open11.89Pre Close430.28MTurnover2.27%Turnover Ratio46.53P/E (Static)1.60BShares19.1752wk High2.03P/B19.01BFloat Cap9.7852wk Low14.27Limit Up1.56BShs Float96.68Historical High9.51Limit Down3.62%Amplitude3.57Historical Low0.01Dividend TTM12.17Avg Price157.63KlotAsk0.08%Div YieldTTM100Lot Size185.49KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Chinese Drug Administration Accepts Walvax Biotechnology's Application to Trial Upgraded Pneumococcal Vaccine
Walvax Biotechnology (300142.SZ): Termination of clinical research on the adsorption-free acellular DTP b influenza Haemophilus influenzae combined vaccine.
On January 21, Glonghui reported that Walvax Biotechnology (300142.SZ) announced that the "Adsorbed Acellular Diphtheria, Tetanus, Pertussis/B type Influenza Haemophilus Influenzae Combined Vaccine" (hereinafter referred to as the "DTaP-Hib Quadrivalent Vaccine") developed jointly by the company and its subsidiary Yuxi Walvax Biotechnology Co., Ltd. obtained the "Drug Clinical Trial Approval Notification" in March 2022, acceptance number: CXSL2101502. Subsequently, the company organized relevant clinical research work according to the requirements. The DTaP-Hib Quadrivalent Vaccine is intended for vaccination of infants aged over 3 months to prevent whooping cough, diphtheria, tetanus, and other diseases.
Express News | Walvax Biotechnology: Termination of clinical research on DTaP-Hib quadrivalent vaccine.
Express News | Walvax Biotechnology: The clinical research application for the 20-valent pneumococcal polysaccharide conjugate vaccine has been accepted.
Watson Biotech: 2024 Annual Results Forecast
Walvax Biotechnology (300142.SZ): Expected net income for the year 2024 is between 0.14 billion yuan and -0.18 billion yuan.
Gelonghui, January 20th丨Walvax Biotechnology (300142.SZ) announced its earnings forecast for 2024. The net income attributable to shareholders of the listed company is expected to be 0.14 billion yuan to 0.18 billion yuan, which represents a year-on-year decline of 57% to 67%; the net income after deducting non-recurring gains and losses is expected to be 0.11 billion yuan to 0.15 billion yuan, a year-on-year decrease of 74% to 81%; revenue is approximately 2.86 billion yuan. During the reporting period, the company's 13-valent pneumococcal polysaccharide conjugate vaccine maintained the largest market share domestically; however, it was impacted by a decline in the number of newborns and increased market competition.
